Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | GHSR | Q92847 | 3/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602235 | 1.00 | ROCK2 (0.50) | ROCK2USP30KDM5APYGLCFTR | |
| SCHEMBL3604732 | 0.94 | GHSR (0.49) | ROCK2USP30KDM5APYGLCFTR | |
| SCHEMBL3604730 | 0.94 | GHSR (0.49) | ROCK2USP30KDM5APYGLCFTR | |
| SCHEMBL3610770 | 0.84 | DRD4 (0.57) | ROCK2USP30KDM5APYGLGHSR | |
| SCHEMBL3607516 | 0.84 | ALOX15 (0.56) | ROCK2USP30PYGLHRH4SMYD3 | |
| SCHEMBL3608594 | 0.84 | ALOX15 (0.56) | ROCK2USP30PYGLHRH4SMYD3 | |
| SCHEMBL3610774 | 0.84 | DRD4 (0.57) | ROCK2USP30KDM5APYGLGHSR | |
| SCHEMBL3607511 | 0.84 | ALOX15 (0.56) | ROCK2USP30PYGLHRH4SMYD3 | |
| SCHEMBL3605930 | 0.80 | SMYD3 (0.46) | USP30CFTRHDAC3HDAC1MLLT1 | |
| SCHEMBL3605926 | 0.80 | SMYD3 (0.46) | USP30CFTRHDAC3HDAC1MLLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | ROCK2 544/4885USP30 1976/4885KDM5A 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.